Not known Factual Statements About semaglutide Week 1-6 Bundle
The demo attained equally its primary endpoints, with semaglutide 2.4 mg demonstrating statistically sizeable and top-quality improvements in liver fibrosis without having worsening of steatohepatitis, and resolution of steatohepatitis without worsening of liver fibrosis in individuals with MASH as compared to placebo.oneBased on animal copy report